Company profile HARP
After 39 days of this quarter the interest is at 164.0. Based on that we can calculate that during remaining 52 days it will total up to 383.0. Harpoon Therapeutics news expected interest is significantly higher compared to previous quarter (+201.6%) and same quarter last year (+204.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 142 inf% QoQ | 62 -56.3% QoQ | 53 -14.5% QoQ |
| 2020 | 226 inf% YoY 326.4% QoQ | 134 -5.6% YoY -40.7% QoQ | 194 212.9% YoY 44.8% QoQ | 198 273.6% YoY 2.1% QoQ |
| 2021 | 59 -73.9% YoY -70.2% QoQ | 94 -29.9% YoY 59.3% QoQ | 56 -71.1% YoY -40.4% QoQ | 32 -83.8% YoY -42.9% QoQ |
| 2022 | 186 215.3% YoY 481.2% QoQ | 166 76.6% YoY -10.8% QoQ | 113 101.8% YoY -31.9% QoQ | 38 18.8% YoY -66.4% QoQ |
| 2023 | 126 -32.3% YoY 231.6% QoQ | 0 -100.0% YoY -100.0% QoQ | 161 42.5% YoY inf% QoQ | 127 234.2% YoY -21.1% QoQ |
| 2024 | 164 30.2% YoY 29.1% QoQ | - | - | - |
The average 5 years interest of Harpoon Therapeutics news was 8.93 per week. The last year interest of Harpoon Therapeutics news compared to the last 5 years has changed by 9.18%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 48.63%.
After 39 days of this quarter the interest is at 118.0. Based on that we can calculate that during remaining 52 days it will total up to 275.0. Harpoon Therapeutics stock expected interest is significantly higher compared to previous quarter (+51.1%) and same quarter last year (+202.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 56 | 47 -16.1% QoQ | 78 66.0% QoQ | 22 -71.8% QoQ |
| 2020 | 28 -50.0% YoY 27.3% QoQ | 22 -53.2% YoY -21.4% QoQ | 48 -38.5% YoY 118.2% QoQ | 63 186.4% YoY 31.2% QoQ |
| 2021 | 25 -10.7% YoY -60.3% QoQ | 57 159.1% YoY 128.0% QoQ | 45 -6.2% YoY -21.1% QoQ | 114 81.0% YoY 153.3% QoQ |
| 2022 | 145 480.0% YoY 27.2% QoQ | 87 52.6% YoY -40.0% QoQ | 93 106.7% YoY 6.9% QoQ | 127 11.4% YoY 36.6% QoQ |
| 2023 | 91 -37.2% YoY -28.3% QoQ | 69 -20.7% YoY -24.2% QoQ | 126 35.5% YoY 82.6% QoQ | 182 43.3% YoY 44.4% QoQ |
| 2024 | 118 29.7% YoY -35.2% QoQ | - | - | - |
The average 5 years interest of Harpoon Therapeutics stock was 6.3 per week. The last year interest of Harpoon Therapeutics stock compared to the last 5 years has changed by 69.05%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 173.08%.
There is not enough data for Harpoon Therapeutics clinical trials to provide analysis
There is not enough data for Harpoon Therapeutics clinical trials to provide correlation calculation
There is not enough data for Harpoon Therapeutics clinical trials to provide analysis
There is not enough data for Harpoon Therapeutics immunotherapy to provide analysis
There is not enough data for Harpoon Therapeutics immunotherapy to provide correlation calculation
There is not enough data for Harpoon Therapeutics immunotherapy to provide analysis
There is not enough data for Harpoon Therapeutics TriTAC to provide analysis
There is not enough data for Harpoon Therapeutics TriTAC to provide correlation calculation
There is not enough data for Harpoon Therapeutics TriTAC to provide analysis
There is not enough data for Harpoon Therapeutics cancer treatment to provide analysis
There is not enough data for Harpoon Therapeutics cancer treatment to provide correlation calculation
There is not enough data for Harpoon Therapeutics cancer treatment to provide analysis
There is not enough data for Harpoon Therapeutics Delta-like canonical Notch ligand 3 to provide analysis
There is not enough data for Harpoon Therapeutics Delta-like canonical Notch ligand 3 to provide correlation calculation
There is not enough data for Harpoon Therapeutics Delta-like canonical Notch ligand 3 to provide analysis
There is not enough data for Harpoon Therapeutics multiple myeloma to provide analysis
There is not enough data for Harpoon Therapeutics multiple myeloma to provide correlation calculation
There is not enough data for Harpoon Therapeutics multiple myeloma to provide analysis
There is not enough data for Harpoon Therapeutics solid tumor indications to provide analysis
There is not enough data for Harpoon Therapeutics solid tumor indications to provide correlation calculation
There is not enough data for Harpoon Therapeutics solid tumor indications to provide analysis